glp-1 law suit Trends to watch: drugs, biosimilars, PBM lawsuit GLP-1 Product Lawsuit: Justpoint |

Long-term application is usually necessary before you see results

Chapter 15 , Unit 15A.1 (2008)

These drugs also have low uptake (less than 2% in the USA) due to several factors, including patients reluctance to seek treatment, lack of addiction training among healthcare providers and considerable stigma surrounding AUD and addiction. - Lorenzo Leggio, et al, Nature Medicine, December 2023 Based on the percentage of people in the United States with alcohol use disorder (11% or ~29.5 million) and the number of people who have received medication for alcohol use disorder in the past year (624,000) and the number of people taking GLP-1 drugs (7 percent of American adults or 18 million), we roughly estimate that more than 3 times as many people with AUD have been incidentally prescribed a GLP-1 in the past year than have been prescribed a medication that is FDA indicated for alcohol use disorder (~2 million vs 624,000, and these groups may overlap)

The GLOW vs KLOW comparison covers the blend options that include GHK-Cu

Common ingredients include methionine, inositol, choline (collectively known as MIC), and often B vitamins including B12